This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Industry Outlook Highlights: UnitedHealth Group, Anthem, Humana and Centene Corp
by Zacks Equity Research
Zacks Industry Outlook Highlights: UnitedHealth Group, Anthem, Humana and Centene Corp
4 HMO Stocks in Focus as Government Backs Healthcare Reform
by Sapna Bagaria
The Health insurance industry is poised to grow on the back of a better regulatory environment. Aging demography, automation plus mergers and acquisitions are other catalysts.
Humana (HUM), Curant Health Team Up to Aid Chronic Patients
by Zacks Equity Research
Humana (HUM) inks a deal with Curant Health to offer its members with chronic diseases enriched healthcare facilities.
Why Is Humana (HUM) Down 6.5% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
UnitedHealth Group (UNH) Arm Wins Medicaid Contract in Nevada
by Zacks Equity Research
UnitedHealth Group's (UNH) Nevada unit aims to get better health outcomes of the state's Medicaid beneficiaries via its recent Medicaid program contract win in the counties of Clark and Washoe.
Humana (HUM) Acquires Remaining Shares at Kindred at Home
by Zacks Equity Research
Humana (HUM) closes its Kindred at Home buyout to bolster its home health and hospice business.
Molina (MOH) Arm's Medicaid Contract to Aid Service in Nevada
by Zacks Equity Research
Molina's (MOH) Nevada unit intends to improve the health outcomes of the state's Medicaid members through its recent contract win from the Nevada Department of Health and Human Services - DHCFP.
Centene (CNC) Nevada Unit Gets Contract to Aid Medicaid Members
by Zacks Equity Research
Centene's (CNC) recent contract win aims to enhance health outcomes for Medicaid members of Nevada.
Magellan (MGLN) Unveils Program to Improve Members' Mental Health
by Zacks Equity Research
Magellan's (MGLN) unit - Magellan Healthcare - launched eMbolden program for offering improved behavioral health outcomes for employees and specific clients.
Centene's (CNC) Contract Win to Aid Medicaid Members in Ohio
by Zacks Equity Research
Centene's (CNC) Ohio subsidiary intends to improve health outcomes of the state's Medicaid members through the recent contract win from the Ohio Department of Medicaid.
Clover Health (CLOV) Stock Rises on Impressive Q2 Revenues
by Zacks Equity Research
Share value of Clover Health (CLOV) hits through the roof on the back of a solid revenue and earnings outlook.
Magellan (MGLN) Q2 Earnings Decline Y/Y on High Expenses
by Zacks Equity Research
Magellan Health's (MGLN) second-quarter results dampened by escalating expenses, partly offset by growth in revenues and Healthcare segment.
Cigna (CI) Q2 Earnings Beat on Revenue Growth But Shares Fall
by Zacks Equity Research
Cigna's (CI) better-than-expected Q2 earnings benefit from better revenues, partly offset by higher medical cost.
Esperion (ESPR) Q2 Loss Narrower Than Expected, Drug Price Up
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings but misses the same for sales. Stock down.
What's in Store for Cigna's (CI) Earnings in Q2?
by Zacks Equity Research
Cigna's (CI) Q2 results are likely to reflect an increase in revenues but a decline in its bottom line.
Community Health (CYH) Q2 Earnings Beat, Hikes '21 EPS View
by Zacks Equity Research
Community Health's (CYH) second-quarter results indicate higher revenues and strong admission growth, partly offset by elevated expenses.
Humana's (HUM) Q2 Earnings Surpass Estimates, Tumble Y/Y
by Zacks Equity Research
Humana's (HUM) second-quarter earnings gain from higher revenues and strong performances by its Retail and Healthcare Services segments.
Humana (HUM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 0.44% and 0.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) to Announce Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Humana's (HUM) second-quarter earnings results to reflect a steep expense level, partly offset by better revenues.
Should You Invest in the SPDR S&P Health Care Services ETF (XHS)?
by Zacks Equity Research
Sector ETF report for XHS
Analysts Estimate Humana (HUM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC), Microsoft Team Up to Offer Better Virtual Care
by Zacks Equity Research
Teladoc Health (TDOC) collaborates with Microsoft in a bid to ease administrative workflows for clinicians and offer enhanced virtual care to patients.
Is a Beat in the Cards for Anthem (ANTM) in Q2 Earnings?
by Zacks Equity Research
Anthem's (ANTM) second-quarter results are likely to benefit on the back of higher premiums coupled with growing Medicaid and Medicare membership, partly offset by escalating costs.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Humana (HUM): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Humana (HUM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.